Hims & Hers Health Adjusts EBITDA Guidance, Shares Drop
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Source: CNBC
- Hims & Hers Guidance Cut: Hims & Hers Health has guided for adjusted EBITDA between $35 million and $55 million for the current quarter, significantly below analysts' expectations of $70 million, resulting in a more than 6% drop in shares, indicating market concerns over its profitability.
- Aecom Earnings Guidance Raised: Aecom raised its full-year adjusted earnings guidance to between $5.90 and $6.10 per share, exceeding previous estimates of $5.85 to $6.05, leading to a 2% increase in stock price, reflecting strong performance in the infrastructure consulting sector.
- Webtoon Revenue Miss: Webtoon Entertainment projected second-quarter revenue between $332 million and $342 million, falling short of the $348 million expected by analysts, causing a 15% drop in shares, which reflects market disappointment regarding its growth outlook.
- Gitlab Restructuring Plan Announced: Gitlab CEO Bill Staples outlined a broad restructuring plan involving workforce reductions and management cuts, resulting in an 8% decline in shares during after-hours trading, signaling market apprehension about the company's strategic shift towards agentic AI.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 27.510
Low
16.50
Averages
32.95
High
60.00
Current: 27.510
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Acquires Eucalyptus to Expand Canadian Market Reach
- Acquisition Completed: Hims & Hers has finalized its acquisition of Eucalyptus, marking a significant investment in the Canadian market that is expected to enhance its competitive edge in personalized health management.
- Market Pioneer: Since its launch in 2025, Hims & Hers has become the first platform to offer generic semaglutide to eligible Canadians, addressing the growing demand for personalized weight management solutions.
- Service Expansion: By integrating Juniper's platform, Hims & Hers will be able to provide a broader range of health services, including sexual health and hair loss treatments, filling critical service gaps in Canada.
- Localized Operations: Hims & Hers emphasizes collaboration with local healthcare providers to ensure patients receive care backed by local expertise and support, thereby enhancing patient trust and satisfaction.
See More
Hims & Hers Faces Uncertainty Over GLP-1 Drug Profits
- Cautious Rating Maintained: Leerink has maintained a 'Market Perform' rating and a $25 price target for Hims & Hers, indicating a 10% downside from current levels, reflecting uncertainty regarding future profits from branded GLP-1 drugs, particularly Wegovy sales and Zepbound facilitation.
- Impact of Eucalyptus Acquisition: Hims & Hers completed its acquisition of digital health platform Eucalyptus a month ahead of schedule, which could enhance revenue guidance; however, the company's stock performance will likely depend on its ability to transition within the competitive GLP-1 market.
- Political Scrutiny Pressure: Senator Jim Banks has urged the FDA to review Hims' GLP-1 advertising, pricing, and subscription practices, increasing political scrutiny on its weight-loss business, which may affect the company's market reputation and sales strategies.
- Enhanced Long-term Confidence: The acquisition of Eucalyptus positions Hims & Hers as the 'world's largest consumer health platform' and reinforces confidence in its long-term targets of $6.5 billion in revenue and $1.3 billion in EBITDA by 2030, despite facing market volatility in the short term.
See More
Hims & Hers Completes Acquisition of Eucalyptus for $240M
- Acquisition Completed: Hims & Hers Health has finalized its acquisition of Eucalyptus, paying approximately $240 million in cash, thereby gaining access to markets in Australia, Canada, and Japan, significantly expanding its international business footprint.
- Market Expansion: Eucalyptus is the parent company of Juniper, Pilot, Kin, and Software, and this acquisition allows Hims & Hers to leverage Eucalyptus's brands and technology, enhancing its competitive position in the global telehealth market.
- Strategic Implications: By acquiring Eucalyptus, Hims & Hers not only enters new markets but also capitalizes on Eucalyptus's existing customer base and product offerings, driving future revenue growth and increasing market share.
- Investor Confidence: Following the acquisition announcement, Hims & Hers's stock price rose, indicating a positive market reaction to its expansion strategy and further bolstering investor confidence in the company's future prospects.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers stock exhibited significant volatility during afternoon trading on May 28, 2026, reflecting market uncertainty regarding its future performance, which could impact investor confidence.
- Price Dynamics: As of May 28, 2026, Hims & Hers stock rose by 6.20%, indicating a positive market reaction in the short term, but the long-term trend remains to be seen to assess sustainability.
- Investor Attention: Due to its volatility, Hims & Hers has become a focal point for investors, potentially attracting short-term traders and those with higher risk appetites, thereby affecting its market liquidity.
- Video Release Impact: The video published on May 30, 2026, may further influence market perceptions of Hims & Hers stock, particularly in analyzing its volatility and future potential.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers (NYSE: HIMS) is identified as one of the most volatile stocks in the market, indicating investor uncertainty regarding its future performance, which could adversely affect its short-term stock price.
- Lack of Investment Recommendations: Despite the attention surrounding Hims & Hers Health, it was not included in the current top 10 stocks recommended by The Motley Fool Stock Advisor, reflecting a cautious market sentiment about its growth potential.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which achieved returns of 463,900% and 1,294,401% respectively, Hims & Hers' absence from the recommendation list highlights its relative disadvantage in the eyes of investors.
- Investor Community Engagement: Although Hims & Hers is not recommended, The Motley Fool still holds shares in the company, indicating its significance within the investor community and potentially attracting investors interested in high-risk opportunities.
See More
Hims & Hers Expands Health Services Partnerships
- Partnership Expansion: Hims & Hers has added eight new partners to its Benefits program, broadening its service offerings in fitness, nutrition, and women's health, which enhances its competitive position as a comprehensive healthcare platform.
- International Market Entry: The company launched generic Semaglutide in Canada, marking its first international rollout of a generic GLP-1 product, which is expected to drive international expansion of its weight-loss business and diversify revenue streams.
- AI Healthcare Innovation: Hims introduced Labs AI, providing personalized analysis of lab results and health risks, indicating a strategic move into AI healthcare tools aimed at improving user experience and health management capabilities.
- Investor Sentiment Fluctuation: While former Netflix CFO David Wells' purchase of Hims shares signals confidence, Bank of America has lowered its price target, reflecting market skepticism about the company's growth prospects amid increasing competition in the GLP-1 market.
See More
Hims & Hers Acquires Eucalyptus to Expand Canadian Market Reach
- Acquisition Completed: Hims & Hers has finalized its acquisition of Eucalyptus, marking a significant investment in the Canadian market that is expected to enhance its competitive edge in personalized health management.
- Market Pioneer: Since its launch in 2025, Hims & Hers has become the first platform to offer generic semaglutide to eligible Canadians, addressing the growing demand for personalized weight management solutions.
- Service Expansion: By integrating Juniper's platform, Hims & Hers will be able to provide a broader range of health services, including sexual health and hair loss treatments, filling critical service gaps in Canada.
- Localized Operations: Hims & Hers emphasizes collaboration with local healthcare providers to ensure patients receive care backed by local expertise and support, thereby enhancing patient trust and satisfaction.
See More
Hims & Hers Faces Uncertainty Over GLP-1 Drug Profits
- Cautious Rating Maintained: Leerink has maintained a 'Market Perform' rating and a $25 price target for Hims & Hers, indicating a 10% downside from current levels, reflecting uncertainty regarding future profits from branded GLP-1 drugs, particularly Wegovy sales and Zepbound facilitation.
- Impact of Eucalyptus Acquisition: Hims & Hers completed its acquisition of digital health platform Eucalyptus a month ahead of schedule, which could enhance revenue guidance; however, the company's stock performance will likely depend on its ability to transition within the competitive GLP-1 market.
- Political Scrutiny Pressure: Senator Jim Banks has urged the FDA to review Hims' GLP-1 advertising, pricing, and subscription practices, increasing political scrutiny on its weight-loss business, which may affect the company's market reputation and sales strategies.
- Enhanced Long-term Confidence: The acquisition of Eucalyptus positions Hims & Hers as the 'world's largest consumer health platform' and reinforces confidence in its long-term targets of $6.5 billion in revenue and $1.3 billion in EBITDA by 2030, despite facing market volatility in the short term.
See More
Hims & Hers Completes Acquisition of Eucalyptus for $240M
- Acquisition Completed: Hims & Hers Health has finalized its acquisition of Eucalyptus, paying approximately $240 million in cash, thereby gaining access to markets in Australia, Canada, and Japan, significantly expanding its international business footprint.
- Market Expansion: Eucalyptus is the parent company of Juniper, Pilot, Kin, and Software, and this acquisition allows Hims & Hers to leverage Eucalyptus's brands and technology, enhancing its competitive position in the global telehealth market.
- Strategic Implications: By acquiring Eucalyptus, Hims & Hers not only enters new markets but also capitalizes on Eucalyptus's existing customer base and product offerings, driving future revenue growth and increasing market share.
- Investor Confidence: Following the acquisition announcement, Hims & Hers's stock price rose, indicating a positive market reaction to its expansion strategy and further bolstering investor confidence in the company's future prospects.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers stock exhibited significant volatility during afternoon trading on May 28, 2026, reflecting market uncertainty regarding its future performance, which could impact investor confidence.
- Price Dynamics: As of May 28, 2026, Hims & Hers stock rose by 6.20%, indicating a positive market reaction in the short term, but the long-term trend remains to be seen to assess sustainability.
- Investor Attention: Due to its volatility, Hims & Hers has become a focal point for investors, potentially attracting short-term traders and those with higher risk appetites, thereby affecting its market liquidity.
- Video Release Impact: The video published on May 30, 2026, may further influence market perceptions of Hims & Hers stock, particularly in analyzing its volatility and future potential.
See More
Analysis of Hims & Hers Stock Volatility
- Market Volatility: Hims & Hers (NYSE: HIMS) is identified as one of the most volatile stocks in the market, indicating investor uncertainty regarding its future performance, which could adversely affect its short-term stock price.
- Lack of Investment Recommendations: Despite the attention surrounding Hims & Hers Health, it was not included in the current top 10 stocks recommended by The Motley Fool Stock Advisor, reflecting a cautious market sentiment about its growth potential.
- Historical Return Comparison: Compared to previously recommended stocks like Netflix and Nvidia, which achieved returns of 463,900% and 1,294,401% respectively, Hims & Hers' absence from the recommendation list highlights its relative disadvantage in the eyes of investors.
- Investor Community Engagement: Although Hims & Hers is not recommended, The Motley Fool still holds shares in the company, indicating its significance within the investor community and potentially attracting investors interested in high-risk opportunities.
See More
Hims & Hers Expands Health Services Partnerships
- Partnership Expansion: Hims & Hers has added eight new partners to its Benefits program, broadening its service offerings in fitness, nutrition, and women's health, which enhances its competitive position as a comprehensive healthcare platform.
- International Market Entry: The company launched generic Semaglutide in Canada, marking its first international rollout of a generic GLP-1 product, which is expected to drive international expansion of its weight-loss business and diversify revenue streams.
- AI Healthcare Innovation: Hims introduced Labs AI, providing personalized analysis of lab results and health risks, indicating a strategic move into AI healthcare tools aimed at improving user experience and health management capabilities.
- Investor Sentiment Fluctuation: While former Netflix CFO David Wells' purchase of Hims shares signals confidence, Bank of America has lowered its price target, reflecting market skepticism about the company's growth prospects amid increasing competition in the GLP-1 market.
See More
